Stanford University

Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor

Retrieved on: 
Wednesday, October 5, 2022

Dr. McHutchison will continue to serve on Assembly Bios Board of Directors, including assuming the role of chairman of the Science and Technology Committee.

Key Points: 
  • Dr. McHutchison will continue to serve on Assembly Bios Board of Directors, including assuming the role of chairman of the Science and Technology Committee.
  • Assembly Bios Board of Directors has unanimously elected Jason A. Okazaki, the companys current president and chief operating officer (COO), as chief executive officer and a member of the board upon Dr. McHutchisons retirement.
  • In partnership with our management team and me, he has enabled Assembly Bio to expand beyond core inhibition into complementary HBV-cure mechanisms and other novel viral targets.
  • The Board and I are grateful for the tremendous progress Assembly Bio has made under Johns leadership, said William R. Ringo, Jr., chairman of the Assembly Bio Board of Directors.

InterVenn Biosciences Co-Founder Carolyn Bertozzi Awarded Nobel Prize in Chemistry

Retrieved on: 
Wednesday, October 5, 2022

InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced that its co-founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in chemistry.

Key Points: 
  • InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced that its co-founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in chemistry.
  • "Dr. Carolyn Bertozzi's receipt of the Nobel Prize underscores the significant contributions she has made in shaping the future of disease screening, clinical decision-making and therapeutics, said Aldo Carrascoso, Co-Founder and CEO of InterVenn Biosciences.
  • We have leveraged Dr. Bertozzis breakthroughs to answer the fundamental questions about sugar proteins, and the Nobel Prize that she received today is validation of her important work.
  • Dr. Bertozzi is the Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences, and a professor of chemistry at Stanford University.

Commitment to Design for Higher Ed Wins Project6 Design Two Silver Medals

Retrieved on: 
Wednesday, October 5, 2022

EMERYVILLE, Calif., Oct. 5, 2022 /PRNewswire-PRWeb/ -- For this competitive season, Project6 Design walks away with three silver awards in the MUSE Awards competition. The first win was for the redesign and development of the Flathead Valley Community College in Montana. The second was a website redesign for a prominent university based in San Francisco. These latest awards highlight their commitment to design for higher education.

Key Points: 
  • The Season 2 winners for the 2022 MUSE Creative and Design Awards had been officially announced by the International Awards Associate (IAA).
  • EMERYVILLE, Calif., Oct. 5, 2022 /PRNewswire-PRWeb/ -- For this competitive season, Project6 Design walks away with three silver awards in the MUSE Awards competition.
  • These latest awards highlight their commitment to design for higher education .
  • Project6 is a 21 year old, award-winning design firm working with primarily with education and nonprofit organizations.

ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia

Retrieved on: 
Wednesday, October 5, 2022

FREMONT, CA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that its Vitrargus Phase II study plan was approved by the Australian Bellberry Human Research Ethics Committee (HREC) on September 29, 2022.

Key Points: 
  • FREMONT, CA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that its Vitrargus Phase II study plan was approved by the Australian Bellberry Human Research Ethics Committee (HREC) on September 29, 2022.
  • Subsequently, a Clinical Trial Notification (CTN) was submitted to the Australian Therapeutic Goods Administration (TGA) for the initiation of the study in Australia.
  • The Phase II study will be conducted in Thailand as well as Australia and will include a total of at least 40 subjects.
  • ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development.

Brijesh Jeevarathnam to Succeed Kelly Meldrum as Global Head of Fund Investments at Adams Street Partners

Retrieved on: 
Wednesday, October 5, 2022

Adams Street Partners , LLC, a private markets investment firm with more than $50 billion of assets under management, announced today that Brijesh Jeevarathnam will be promoted to Partner & Global Head of Fund Investments.

Key Points: 
  • Adams Street Partners , LLC, a private markets investment firm with more than $50 billion of assets under management, announced today that Brijesh Jeevarathnam will be promoted to Partner & Global Head of Fund Investments.
  • View the full release here: https://www.businesswire.com/news/home/20221005005265/en/
    Brijesh Jeevarathnam has been promoted to Partner & Global Head of Fund Investments of Adams Street Partners.
  • (Photo: Business Wire)
    Jeevarathnam succeeds Kelly Meldrum , who is retiring after 17 years as a Partner & Head of Primary Investments at the firm.
  • Adams Street Partners is a global private markets investment manager with investments in more than thirty countries across five continents.

CAIA Association Unveils the Guiding Principles for Investment Professionals That Will Drive Implementation of The Portfolio for the Future™

Retrieved on: 
Wednesday, October 5, 2022

The Chartered Alternative Investment Analyst (CAIA) Association today unveiled a new report, titled A Renewed Professionalism, that provides specific, actionable guiding principles for investment professionals as they work to implement the Portfolio for the Future.

Key Points: 
  • The Chartered Alternative Investment Analyst (CAIA) Association today unveiled a new report, titled A Renewed Professionalism, that provides specific, actionable guiding principles for investment professionals as they work to implement the Portfolio for the Future.
  • Calling this report A Renewed Professionalism was a very specific and very pointed choice, said William J. Kelly, CAIA, Chief Executive Officer of the CAIA Association.
  • A Member-driven organization representing nearly 13,000 professionals in approximately 100 countries, CAIA Association advocates for the highest ethical standards.
  • To learn more about the CAIA Association and how to become part of the organizations mission, please visit https://caia.org/ .

Human Life Is a Human Right: National Movement Rallies to Answer "Why We're Pro-Life"

Retrieved on: 
Wednesday, October 5, 2022

EL CAJON, Calif., Oct. 5, 2022 /PRNewswire-PRWeb/ -- In the wake of new state ballot initiatives to enshrine the right to kill the unborn and the vandalization of houses of worship and pro-life women's health centers, hundreds of organizations, universities, nonprofits, and advocates from across the nation have come together to declare that human life is a human right.

Key Points: 
  • It's about recognizing the value of human life at all stages and that even at conception, that new human is morally relevant.
  • Unifying the national movement is the distribution of copies of " Why We're Pro-Life ," a new, free booklet from pro-life defender Trent Horn.
  • ", and more, while offering science-based answers and fact-driven reasoning pointing to the universal truth: human life begins at conception.
  • "It's about recognizing the value of human life at all stages and that even at conception, that new human is morally relevant."

California Water Service Group Announces Board Appointments

Retrieved on: 
Tuesday, October 4, 2022

SAN JOSE, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- California Water Service Group (NYSE: CWT) today announced that its Board has nominated Terry P. Bayer to assume the role of Lead Independent Director, effective immediately.

Key Points: 
  • SAN JOSE, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- California Water Service Group (NYSE: CWT) today announced that its Board has nominated Terry P. Bayer to assume the role of Lead Independent Director, effective immediately.
  • California Water Service Group is the parent company of regulated utilities California Water Service, Hawaii Water Service, New Mexico Water Service, Washington Water Service, and Texas Water Service, a utility holding company.
  • Together, these companies provide regulated and non-regulated water and wastewater service to more than 2 million people in California, Hawaii, New Mexico, Texas, and Washington.
  • California Water Service Groups common stock trades on theNew York Stock Exchangeunder the symbol CWT.

TruckLabs Reaches Half Billion Over-the-Road Miles with Aerodynamic TruckWings

Retrieved on: 
Tuesday, October 4, 2022

PHOENIX, Oct. 4, 2022 /PRNewswire-PRWeb/ -- TruckLabs, a trucking technology company that creates intelligent solutions that positively impact carbon reduction while improving operational efficiencies, has announced it has reached a half-billion miles driven with its TruckWings device, a critical benchmark resulting in approximately 32,648 metric tons of CO2 saved to date - or the equivalent of removing a year's worth of emissions from over 7,000 passenger cars.

Key Points: 
  • TruckWings is a fully automated, smart aerodynamic device built for trucking fleets and they are currently deployed on 5 of the largest fleets in North America.
  • It's a huge credit to the team's engineering work to hit this milestone so quickly," said TruckLabs Founder & CEO Daniel Burrows.
  • "TruckWings help fleets reduce fuel costs and emissions today and will improve the range of electric trucks in the future."
  • Its flagship technology, TruckWings, is a tractor-mounted, smart aerodynamic device that automatically closes the gap between cab and trailer to reduce drag, improve stability, and increase fuel efficiency.

Saluda Medical Appoints Laureen DeBuono to Board of Directors

Retrieved on: 
Tuesday, October 4, 2022

ARTARMON, Australia, Oct. 4, 2022 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical"), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced neural activation and sensing technologies, today announced the appointment of Laureen DeBuono to its board of directors.

Key Points: 
  • ARTARMON, Australia, Oct. 4, 2022 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical"), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced neural activation and sensing technologies, today announced the appointment of Laureen DeBuono to its board of directors.
  • "Laureen's extensive background across operational and strategic levels at both public and private companies, as well as her director level experience, speaks for itself," said Jim Schuermann, president and CEO of Saluda Medical.
  • DeBuono is a seasoned executive who has served in a multitude of senior executive level roles at various private and public companies across the healthcare and consumer sectors.
  • Currently, she is a managing partner at FLG Partners, focusing on interim CEO, CFO, and board advisory services, as well as executive coaching.